Merck & Co has been fighting to defend its blockbuster type 2 diabetes therapy Januvia from generic competition for years, and a new judgment looks set to protect its third biggest-selling drug ...
Investor's Business Daily on MSN7mon
Medicare Slashes Merck, Novo, AstraZeneca Drug Prices Up To 79% In IRA NegotiationsThe negotiations lowered the price Medicare will pay for Merck's Januvia, Novo's Fiasp and AstraZeneca's Farxiga by a ...
Meanwhile Steglujan (ertugliflozin+sitagliptin), a fixed dose combination combining the SGLT2 with Merck’s Januvia, is approved in type 2 disease when patients who need both drugs. Ertugliflozin ...
Delhi HC verdict on Januvia boost for Glenmark: Antique In an interview to CNBC-TV18 pharma analyst, Anmol Ganjoo of Antique Stock Broking said Delhi High court's verdict on Januvia Generic will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback